Literature DB >> 17223763

Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series.

Daniel P O'Brien1, Andrew J Hughes, Allen C Cheng, Margaret J Henry, Peter Callan, Anthony McDonald, Ian Holten, Mike Birrell, John M Sowerby, Paul D R Johnson, Eugene Athan.   

Abstract

OBJECTIVE: To describe the effect of antibiotics on outcomes of treatment for Buruli or Bairnsdale ulcer (BU) in patients on the Bellarine Peninsula in south-eastern Australia.
DESIGN: Observational, non-randomised study with data collected prospectively or through medical record review. PATIENTS AND
SETTING: All 40 patients with BU managed by staff of Barwon Health's Geelong Hospital (a public, secondary-level hospital) between 1 January 1998 and 31 December 2004. MAIN OUTCOME MEASURES: Epidemiology, clinical presentation, diagnosis, treatment and clinical outcomes.
RESULTS: There were 59 treatment episodes; 29 involved surgery alone, 26 surgery plus antibiotics, and four antibiotics alone. Of 55 episodes where surgery was performed, minor surgery was required in 22, and major surgery in 33. Failure rates were 28% for surgery alone, and 19% for surgery plus antibiotics. Adjunctive antibiotic therapy was associated with increased treatment success for lesions with positive histological margins (P < 0.01), and lesions requiring major surgery for treatment of a first episode (P < 0.01). The combination of rifampicin and ciprofloxacin resulted in treatment success in eight of eight episodes, and no patients ceased therapy because of side effects with this regimen.
CONCLUSIONS: Adjunctive antibiotic therapy may increase the effectiveness of BU surgical treatment, and this should be further assessed by larger randomised controlled trials. The combination of rifampicin and ciprofloxacin appears the most promising.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223763

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  19 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

2.  Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment?

Authors:  K-H Herbinger; D Brieske; J Nitschke; V Siegmund; W Thompson; E Klutse; N Y Awua-Boateng; E Bruhl; L Kunaa; M Schunk; O Adjei; T Löscher; G Bretzel
Journal:  Infection       Date:  2008-12-03       Impact factor: 3.553

3.  Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.

Authors:  N Deborah Friedman; Eugene Athan; Aaron L Walton; Daniel P O'Brien
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans.

Authors:  N Deborah Friedman; Anthony H McDonald; Michael E Robson; Daniel P O'Brien
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

5.  All-oral antibiotic treatment for buruli ulcer: a report of four patients.

Authors:  Claire L Gordon; John A Buntine; John A Hayman; Caroline J Lavender; Janet A M Fyfe; Patrick Hosking; Mike Starr; Paul D R Johnson
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

6.  Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.

Authors:  Daniel P O'Brien; Anthony McDonald; Peter Callan; Mike Robson; N Deborah Friedman; Andrew Hughes; Ian Holten; Aaron Walton; Eugene Athan
Journal:  PLoS Negl Trop Dis       Date:  2012-01-17

Review 7.  Pharmacologic management of Mycobacterium ulcerans infection.

Authors:  Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra
Journal:  Expert Rev Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.108

Review 8.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

9.  Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Authors:  Richard O Phillips; Fred S Sarfo; Mohammed K Abass; Justice Abotsi; Tuah Wilson; Mark Forson; Yaw A Amoako; William Thompson; Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

10.  Risk factors for Mycobacterium ulcerans infection, southeastern Australia.

Authors:  Tricia Y J Quek; Eugene Athan; Margaret J Henry; Julie A Pasco; Jane Redden-Hoare; Andrew Hughes; Paul D R Johnson
Journal:  Emerg Infect Dis       Date:  2007-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.